Bupropion News and Research RSS Feed - Bupropion News and Research

Combination of behavioral support and medication helps people stop smoking

Combination of behavioral support and medication helps people stop smoking

Numerous randomized clinical trials have shown the effectiveness of the two major forms of smoking cessation treatment - behavioral support and medication - in helping smokers quit. Researchers have now demonstrated that this approach can successfully translate to the "real world" and that a combination of the two treatments offers almost a threefold chance of success over attempts to quit without using a cessation aid. [More]
FDA approves Contrave extended-release tablets for chronic weight management

FDA approves Contrave extended-release tablets for chronic weight management

Takeda Pharmaceuticals U.S.A., Inc. and Orexigen® Therapeutics, Inc. jointly announced today that the U.S. Food and Drug Administration has approved Contrave® extended-release tablets as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index of 30 kg/m2 or greater (obese), or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition. [More]
Combining 2 smoking cessation therapies more effective for highly nicotine-dependent smokers

Combining 2 smoking cessation therapies more effective for highly nicotine-dependent smokers

Combining two smoking cessation therapies is more effective than using just one for male and highly nicotine-dependent smokers who weren't initially helped by the nicotine patch, according to researchers at Duke Medicine. [More]
New prescription weight-loss medication combines antidepressant with addiction medication

New prescription weight-loss medication combines antidepressant with addiction medication

A new prescription weight-loss medication that combines a popular antidepressant with a medication for addiction will be reviewed by the Federal Drug Administration (FDA) for potential approval. [More]
Study: Combined medications may improve smoking cessation than single drug therapy

Study: Combined medications may improve smoking cessation than single drug therapy

Among cigarette smokers, combining the smoking cessation medications varenicline and bupropion, compared with varenicline alone, resulted in higher smoking abstinence rates for one outcome but not the other at three and six months; rates were similar at one year, according to a Mayo Clinic study published this month in JAMA. [More]
Orexigen Therapeutics reports net loss of $18.6 million in Q3 2013

Orexigen Therapeutics reports net loss of $18.6 million in Q3 2013

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced business and financial results for the third quarter ended September 30, 2013. [More]
Researchers study quality, effectiveness and safety of generic drugs used to treat depression

Researchers study quality, effectiveness and safety of generic drugs used to treat depression

Researchers at Washington University School of Medicine in St. Louis are studying the quality, effectiveness and safety of generic drugs used to treat depression. [More]

IQWiG completes first health economic evaluation

The German Institute for Quality and Efficiency in Health Care has completed its first health economic evaluation. The report on antidepressants published on 30 October 2013 shows that the "efficiency frontier method" works and can provide very helpful results. [More]
Study assesses risk of psychiatric events in patients prescribed smoking cessation drugs

Study assesses risk of psychiatric events in patients prescribed smoking cessation drugs

A study to assess whether patients prescribed smoking cessation drugs are at an increased risk of suicide, self-harm and treated depression compared with users of nicotine replacement therapy has found no evidence of an increased risk. [More]
Depressed smokers may benefit from mood management interventions

Depressed smokers may benefit from mood management interventions

Studies have shown that people with depression are about twice as likely to smoke cigarettes as people without depression and they are less likely to successfully quit than smokers without depression. [More]
Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Smokers with a history of major depressive disorder (MDD) taking varenicline have significantly higher likelihood of quitting smoking than placebo

Results of a Pfizer-commissioned study published this month in Annals of Internal Medicine reveal that smokers with a past or present diagnosis of major depressive disorder (MDD)* taking varenicline had a significantly higher likelihood of quitting smoking (after 12 weeks and at 52 weeks) than those who were given a placebo. [More]
Smokers who try e-cigarettes to quit are younger and more motivated to quit, study finds

Smokers who try e-cigarettes to quit are younger and more motivated to quit, study finds

University of Hawaii Cancer Center Prevention and Control Program researchers Pallav Pokhrel, PhD and Thaddeus Herzog, PhD have found that smokers who use e-cigarettes as a tool to stop smoking tend to be younger and more motivated to quit smoking as compared to other smokers. [More]
Eisai submits BELVIQ NDS with Health Canada

Eisai submits BELVIQ NDS with Health Canada

Arena Pharmaceuticals, Inc. announced today that Eisai Limited (based in Mississauga, Ontario), a subsidiary of Eisai Inc., has submitted a New Drug Submission for BELVIQ (lorcaserin HCl) with Health Canada. [More]
Smokers trying to quit will have better experience with varenicline, study finds

Smokers trying to quit will have better experience with varenicline, study finds

Smokers have a higher probability of quitting smoking and a better overall cessation experience when taking varenicline compared to bupropion and to placebo - unmedicated assisted smoking cessation -according to a study published in the journal JAMA Psychiatry. [More]
Orexigen reports progress with FDA on faster path to Contrave NDA resubmission

Orexigen reports progress with FDA on faster path to Contrave NDA resubmission

Orexigen Therapeutics, Inc., a biopharmaceutical company focused on the treatment of obesity, today announced progress with the United States Food and Drug Administration (FDA) on a faster path to resubmission of the Contrave (naltrexone SR / bupropion SR) New Drug Application (NDA). [More]

Prevention is better than cure for smoking in young people

Behavior-based interventions in the primary care setting reduce the risk for children and adolescents taking up smoking, conclude US investigators who also found that neither behavior- nor drug-based interventions improve cessation rates. [More]
BCPR, Orexigen partner to accelerate patient enrollment for Contrave obesity Light Study

BCPR, Orexigen partner to accelerate patient enrollment for Contrave obesity Light Study

Blue Chip Patient Recruitment, a division of Blue Chip Marketing Worldwide, a full-service integrated marketing agency, has successfully partnered with Orexigen Therapeutics to accelerate patient enrollment of The Light Study, Orexigen's cardiovascular outcomes trial evaluating Contrave (naltrexone sustained release (SR)/bupropion SR). [More]

Behavioural support programme to make TB patients quit smoking receives BUPA Foundation prize

The BUPA Foundation has awarded a high commendation prize for research led by the University of York into effective ways of helping tuberculosis patients in Pakistan to give up smoking. [More]
FTC votes to approve Watson's acquisition of Actavis

FTC votes to approve Watson's acquisition of Actavis

Watson Pharmaceuticals, Inc. today announced that the Federal Trade Commission (FTC) has voted to approve Watson's acquisition of the Actavis group of companies. [More]
Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Enrollment complete in Euthymics’ amitifadine phase 2b/3a trial for major depressive disorder

Euthymics Bioscience, Inc. today announced completion of enrollment in the advanced clinical study of its lead product candidate amitifadine (formerly called EB-1010), a novel serotonin-preferring triple reuptake inhibitor for the treatment of major depressive disorder (MDD). [More]